-
1دورية أكاديمية
المؤلفون: Ruddy, Kathryn J.Aff1, Zheng, Yue, Tayob, Nabihah, Hu, Jiani, Dang, Chau T., Yardley, Denise A., Isakoff, Steven J., Valero, Vicente V., Faggen, Meredith G., Mulvey, Therese M., Bose, Ron, Sella, Tal, Weckstein, Douglas J., Wolff, Antonio C., Reeder-Hayes, Katherine E., Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan S., Hart, Lowell L., Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit L., Briccetti, Frederick M., Schneider, Bryan P., Merrill Garrett, A., Kelly Marcom, P., Albain, Kathy S., DeFusco, Patricia A., Tung, Nadine M., Ardman, Blair M., Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta C., Rosenberg, Shoshana, DeMeo, Michelle K., Burstein, Harold J., Winer, Eric P., Krop, Ian E., Partridge, Ann H., Tolaney, Sara M.
المصدر: Breast Cancer Research and Treatment. 189(1):103-110
-
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
10دورية أكاديمية
المؤلفون: Filho OM; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Viale G; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.; University of Milan, Milan, Italy., Stein S; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Trippa L; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee., Mayer IA; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Abramson VG; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, Texas., Spring LM; Massachusetts General Hospital, Boston, Massachusetts., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Bardia A; Massachusetts General Hospital, Boston, Massachusetts., Dell'Orto P; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Russo L; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., King TA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Polyak K; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts., Michor F; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts.; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ian_Krop@dfci.harvard.edu michor@jimmy.harvard.edu Otto_Metzger@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
المصدر: Cancer discovery [Cancer Discov] 2021 Oct; Vol. 11 (10), pp. 2474-2487. Date of Electronic Publication: 2021 May 03.
نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Antineoplastic Agents, Immunological/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Receptor, ErbB-2/*genetics , Trastuzumab/*therapeutic use, Adult ; Aged ; Breast Neoplasms/genetics ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Treatment Outcome
Find this article in full text from Springer Verlag. 
Full Text Finder